lactic acid has been researched along with Carcinoma, Hepatocellular in 116 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to investigate the effects of Ginsenoside Rh4 (Rh4) on inflammation-related hepatocellular carcinoma (HCC) progression and the underlying mechanism." | 8.31 | Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling. ( Jiang, R; Jiang, X; Luo, S; Qiu, Q; Wang, W; Wu, Y; Yuan, Y; Zhang, M; Zhuo, S, 2023) |
| "Histone lysine lactylation (Kla) plays a vital role in the tumorigenesis of hepatocellular carcinoma (HCC)." | 8.31 | Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma. ( Li, X; Liu, Q; Long, M; Wu, Q; Xie, X, 2023) |
| "To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133." | 7.81 | The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. ( Chen, H; Chen, M; Jiang, J; Sun, C; Tian, S; Yu, C; Zhang, Y, 2015) |
| "To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 cells." | 7.81 | Effect of paclitaxel-loaded nanoparticles on the viability of human hepatocellular carcinoma HepG2 cells. ( Hou, ZH; Zhang, Q; Zhao, WC; Zheng, W, 2015) |
| "Transcatheter arterial chemoembolization therapy using polylactic acid microspheres containing aclarubicin hydrochloride (ACR) was performed in 62 patients with primary hepatocellular carcinoma." | 7.67 | Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. ( Akagi, M; Ichihara, T; Mori, K; Sakamoto, K, 1989) |
| "Targeted hepatocellular carcinoma (HCC) therapy was carried out to improve the efficacy of liver cancers." | 5.43 | Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. ( Li, J; Yan, M; Zhang, X, 2016) |
| "This study aimed to investigate the effects of Ginsenoside Rh4 (Rh4) on inflammation-related hepatocellular carcinoma (HCC) progression and the underlying mechanism." | 4.31 | Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling. ( Jiang, R; Jiang, X; Luo, S; Qiu, Q; Wang, W; Wu, Y; Yuan, Y; Zhang, M; Zhuo, S, 2023) |
| "Histone lysine lactylation (Kla) plays a vital role in the tumorigenesis of hepatocellular carcinoma (HCC)." | 4.31 | Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma. ( Li, X; Liu, Q; Long, M; Wu, Q; Xie, X, 2023) |
| "Stepwise pH-responsive nanoparticle system containing charge reversible pullulan-based (CAPL) shell and poly(β-amino ester) (PBAE)/poly(lactic-co-glycolic acid) (PLAG) core is designed to be used as carriers of paclitaxel (PTX) and combretastatin A4 (CA4) for combining antiangiogenesis and chemotherapy to treat hepatocellular carcinoma (HCC)." | 3.83 | Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma. ( An, T; Li, R; Wan, G; Wang, D; Wang, H; Wang, Y; Yang, X; Zhang, C; Zhang, M; Zhang, S, 2016) |
| "Sorafenib, a multikinase inhibitor, has been used as an anti-angiogenic agent against highly vascular hepatocellular carcinoma (HCC) - yet associated with only moderate therapeutic effect and the high incidence of HCC recurrence." | 3.81 | CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. ( Chang, CC; Chen, Y; Chiang, WH; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC, 2015) |
| "To develop salinomycin-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with both CD133 aptamers A15 and EGFR aptamers CL4 (CESN), to target hepatocellular carcinoma (HCC) cells simultaneously expressing EGFR and CD133." | 3.81 | The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. ( Chen, H; Chen, M; Jiang, J; Sun, C; Tian, S; Yu, C; Zhang, Y, 2015) |
| "To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 cells." | 3.81 | Effect of paclitaxel-loaded nanoparticles on the viability of human hepatocellular carcinoma HepG2 cells. ( Hou, ZH; Zhang, Q; Zhao, WC; Zheng, W, 2015) |
| "In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma." | 3.80 | Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014) |
| " Here, we studied the effect of oxamic and tartronic acids, 2 inhibitors of LDH, on aerobic glycolysis and cell replication of HepG2 and PLC/PRF/5 cells, 2 lines from human hepatocellular carcinomas." | 3.76 | Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines. ( Di Stefano, G; Fiume, L; Manerba, M; Vettraino, M, 2010) |
| "3-BrPA (3-bromopyruvate) is an alkylating agent with anti-tumoral activity on hepatocellular carcinoma." | 3.75 | Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. ( Almeida, FC; Da Poian, AT; da-Silva, WS; dos Santos, RS; El-Bacha, T; Galina, A; Kyaw, N; Pereira da Silva, AP, 2009) |
| " To investigate this hypothesis, we compared the response to an anticancer agent chloroethylnitrosourea (CENU) of two transformed cell lines: HepG2 (hepatocarcinoma) with a partially differentiated phenotype and 143B (osteosarcoma) with an undifferentiated one." | 3.75 | Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy. ( Chevrollier, A; Demidem, A; Douay, O; Loiseau, D; Morvan, D; Reynier, P; Stepien, G, 2009) |
| " However, we experienced a patient with liver cirrhosis (LC, Child-Pugh class B) in whom severe lactic acidosis developed during RFA conducted for the treatment of a HCC (-4." | 3.71 | [Changes in acid-base balance and blood lactate levels during radio frequency ablation conducted for the treatment of hepatocellular carcinomata in patients with liver cirrhosis]. ( Akata, T; Kandabashi, T; Kanna, T; Shiokawa, H; Takahashi, S; Yoshino, J, 2002) |
| "Transcatheter arterial chemoembolization therapy using polylactic acid microspheres containing aclarubicin hydrochloride (ACR) was performed in 62 patients with primary hepatocellular carcinoma." | 3.67 | Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride. ( Akagi, M; Ichihara, T; Mori, K; Sakamoto, K, 1989) |
| "Human HCC-LM3 and SK-Hep-1 hepatoma cells were used and treated with or without osthole, irradiation, or their combination; the cell survival, migration, colony formation, DNA damage repair, intracellular lactic acid content, and glycolysis-related glycogen synthase kinase-3β (GSK-3β), p-GSK-3β, AMP-activated protein kinase (AMPK), p-AMPK, mammalian target of rapamycin (mTOR), p-mTOR, glucose transporter-1 (GLUT-1), GLUT-3, and pyruvate kinase isozyme type M2 (PKM2) protein expressions were determined." | 1.91 | Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis. ( Huang, H; Xie, ML; Xie, T; Xue, J, 2023) |
| "Human hepatocellular carcinoma (HCC) features include enhanced glycolysis and elevated lactate concentrations." | 1.91 | Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites. ( Li, L; Qu, L; Wang, C; Wang, S; Wang, Z; Xu, H; Xu, K, 2023) |
| "Currently, conventional treatments of hepatocellular carcinoma (HCC) are not selective enough for tumor tissue and lead to multidrug resistance and drug toxicity." | 1.91 | Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells. ( Aliberti, A; Buonaguro, L; Caputo, TM; Carriero, MV; Celetti, G; Cicatiello, P; Cusano, A; Cusano, AM; Micco, A; Minopoli, M; Principe, S; Ragone, C; Ruvo, M; Tagliamonte, M, 2023) |
| "Lactic acid has been proved to be an important metabolite involved in cancer development, metastasis, and the tumor microenvironment, affecting the prognosis of patients." | 1.91 | Characteristics of lactate metabolism phenotype in hepatocellular carcinoma. ( Dong, K; Li, C; Wang, W; Yu, J; Zhang, J; Zhang, X, 2023) |
| "Individuals with hepatocellular carcinoma who responded to anti-PD-1 treatment have lower levels of MOESIN lactylation in Treg cells than nonresponding individuals." | 1.72 | Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. ( Chen, Q; Gao, J; Gu, J; Li, X; Liang, Y; Lu, L; Shao, Q; Wang, Q; Wei, S; Xu, X; Zhou, B; Zhou, H; Zhou, J, 2022) |
| "Forced miR-342-3p expression in hepatoma cells showed significantly decreased cell proliferation, migration, and colony formation." | 1.62 | MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. ( Balakrishnan, A; Daon, J; Goga, A; Hu, Q; Komoll, RM; Manns, MP; Olarewaju, O; Ott, M; Qin, R; Sharma, AD; Tsay, HC; von Döhlen, L; Xie, Y; Yuan, Q, 2021) |
| "Among these, hepatocellular carcinoma required lactate dehydrogenase (LDH) for growth more than the 29 other cancer types in this database." | 1.56 | Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer. ( Ackerman, D; Gade, TPF; Johnson, O; Mercadante, M; Perkons, NR; Pilla, G; Profka, E, 2020) |
| "HepaRG is a proliferative human hepatoma-derived cell line that can be differentiated into hepatocyte-like and biliary-like cells." | 1.51 | Comparison of HepaRG cells following growth in proliferative and differentiated culture conditions reveals distinct bioenergetic profiles. ( Young, CKJ; Young, MJ, 2019) |
| "Twenty-nine patients with chronic hepatitis B (CHB), 28 with compensated LC, 33 with decompensated LC, 24 with spontaneous bacterial peritonitis (SBP), 26 with acute-on-chronic liver failure (ACLF), and 24 with decompensated LC complicated by hepatocellular carcinoma (HCC) were recruited." | 1.51 | Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. ( Biviano, I; Gong, Z; Hu, J; Liu, H; Wang, A; Wang, Z, 2019) |
| "Previously, we reported that human hepatoma cells that harbor OXPHOS defects exhibit high tumor cell invasiveness via elevated claudin-1 (CLN1)." | 1.46 | Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. ( Jeoun, UW; Kwon, SM; Lee, C; Lee, EB; Lee, YK; Lim, JJ; Min, S; Yoon, G, 2017) |
| "Targeted hepatocellular carcinoma (HCC) therapy was carried out to improve the efficacy of liver cancers." | 1.43 | Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. ( Li, J; Yan, M; Zhang, X, 2016) |
| "Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs." | 1.43 | Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model. ( Exner, AA; Gangolli, M; Hernandez, C; Solorio, L; Wu, H, 2016) |
| "Treatment options for patients with hepatocellular carcinoma (HCC) are limited, in particular in advanced and drug resistant HCC." | 1.43 | Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. ( Abou Elkacem, L; Bachawal, S; Choe, JW; Devulapally, R; Mullick Chowdhury, S; Paulmurugan, R; Tian, L; Wang, DS; Wang, TY; Willmann, JK; Yakub, BK, 2016) |
| "Oleanolic acid (OA) is a natural triterpenoid, has many important biological actions, including antitumor effect, but its poor solubility often leads to poor pharmacodynamics." | 1.42 | A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment. ( Bao, X; Chu, QC; Gao, M; Guan, X; Jiang, N; Liu, KX; Tian, Y; Xu, H; Zhang, CH, 2015) |
| "Ursolic acid (UA) is a naturally bioactive product that exhibits potential anticancer effects." | 1.40 | Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis. ( Chen, J; Dai, Y; Jia, L; Jiang, Z; Li, Y; Lin, L; Lu, Y; Ou, M; Shao, J; Wang, J; Xiang, L; Yang, X, 2014) |
| "Tanshinone IIA (TAN) has few clinical applications for anti-cancer therapy mainly due to its high lipophicity, low cellular uptake, and poor bioavailability." | 1.40 | TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy. ( Chen, M; Fang, X; Li, Y; Wang, Y; Zhang, J; Zhou, D, 2014) |
| "In our experiments, liver cancer cell lines exhibited a range of sensitivity to PKM2 knockdown-mediated growth inhibition." | 1.39 | Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells. ( Jang, YJ; Jung, Y; Kang, MH; Lee, DC; Oh, SJ; Park, KC; Park, YS; Xie, Z; Yeom, YI; Yoo, HS, 2013) |
| "First, we found that all the SNU human hepatoma cells with increased glycolytic lactate production have the defective mitochondrial respiratory activity and the Cln-1-mediated high invasive activity." | 1.37 | Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects. ( Kim, BW; Kim, EL; Kim, JH; Lee, SJ; Lee, YK; Park, CB; Wang, HJ; Yoon, CH; Yoon, G, 2011) |
| "We used highly proliferative human hepatoma Hep G2 cells to assess the growth-related limitation of such direct oxygen supply." | 1.36 | Spontaneous formation of highly functional three-dimensional multilayer from human hepatoma Hep G2 cells cultured on an oxygen-permeable polydimethylsiloxane membrane. ( Evenou, F; Fujii, T; Sakai, Y, 2010) |
| "Treatment of hepatoma cells with 2." | 1.35 | Glucocorticoid protects hepatoma cells against metabolic stress-induced cell death. ( Chi, CW; Ko, PH; Liu, TY; Lui, WY; Uen, YH; Yin, PH, 2008) |
| "The Wistar rat implantation hepatocellular carcinoma model was set up by inserting the W256 tumor solid piece into Wistar rat's liver." | 1.35 | [Experimental investigation of hepatic arterial embolism treatment with microsphere encapsulation of adenovirus with HSV-TK gene]. ( Li, XX; Liu, ZM; Yan, LN, 2009) |
| "The growth of transplantable syngeneic hepatoma 22a was associated with the absence of correlation between nitrite synthesis by peritoneal macrophages and serum lactate concentration." | 1.33 | Effect of lactate on functional activity of macrophages under normal conditions and during tumor growth. ( Kiseleva, EP; Ogurtsov, RP; Puzyreva, VP, 2006) |
| "Subcapsular implantation of a solid Morris Hepatoma 3 924A (1 mm(3)) in the livers was carried out in 11 male ACI-rats." | 1.32 | Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. ( Claussen, C; Eul, T; Graepler, F; Huppert, P; Pereira, P; Qian, J; Truebenbach, J; Wiemann, G, 2003) |
| "We have shown previously that rat hepatoma FTO-2B cells express two mRNAs, called F (fetal) and L (liver), from distinct promoters of the same gene coding for 6-phosphofructo-2-kinase (PFK-2)." | 1.30 | Glucose response elements in a gene that codes for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. ( Dupriez, VJ; Rousseau, GG, 1997) |
| "In contrast to the hepatoma cells, rat and human hepatocytes exhibited higher rates of anaerobic glycolysis in the presence of fructose and thus were able to maintain their viability under these conditions." | 1.28 | Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes. ( Anundi, I; de Groot, H; Hugo-Wissemann, D; Lauchart, W; Viebahn, R, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.72) | 18.7374 |
| 1990's | 6 (5.17) | 18.2507 |
| 2000's | 20 (17.24) | 29.6817 |
| 2010's | 59 (50.86) | 24.3611 |
| 2020's | 29 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, SI | 1 |
| Kim, MS | 1 |
| Kim, HJ | 1 |
| Kim, YI | 1 |
| Jae, HJ | 1 |
| Ahn, CH | 1 |
| Fang, Y | 1 |
| Liu, W | 3 |
| Tang, Z | 1 |
| Ji, X | 1 |
| Zhou, Y | 4 |
| Song, S | 1 |
| Tian, M | 1 |
| Tao, C | 1 |
| Huang, R | 1 |
| Zhu, G | 1 |
| Jiang, X | 3 |
| Gao, J | 3 |
| Qu, W | 1 |
| Wang, H | 4 |
| Zhou, P | 1 |
| Wu, X | 1 |
| Jin, L | 1 |
| Sun, H | 1 |
| Ding, Z | 1 |
| Peng, Y | 1 |
| Zhao, S | 1 |
| Zhou, J | 2 |
| Fan, J | 1 |
| Xu, W | 1 |
| Shi, Y | 1 |
| Tang, M | 1 |
| Huang, Y | 1 |
| Liang, X | 2 |
| Tao, Y | 1 |
| He, N | 1 |
| Li, Z | 3 |
| Guo, J | 3 |
| Gui, S | 1 |
| Pan, L | 1 |
| Feng, F | 1 |
| Wu, J | 1 |
| Fan, S | 1 |
| Han, J | 1 |
| Wang, S | 3 |
| Yang, L | 4 |
| Wang, C | 2 |
| Xu, K | 2 |
| Han, S | 2 |
| Bi, S | 1 |
| Guo, T | 1 |
| Sun, D | 1 |
| Zou, Y | 2 |
| Wang, L | 2 |
| Song, L | 1 |
| Chu, D | 1 |
| Liao, A | 2 |
| Song, X | 1 |
| Yu, Z | 2 |
| Alves, AP | 1 |
| Rocha, SM | 1 |
| Mamede, AC | 1 |
| Braga, PC | 1 |
| Alves, MG | 1 |
| Oliveira, PF | 1 |
| Botelho, FM | 1 |
| Maia, CJ | 1 |
| Gu, J | 1 |
| Chen, Q | 1 |
| Xu, X | 1 |
| Li, X | 2 |
| Shao, Q | 1 |
| Zhou, B | 2 |
| Zhou, H | 2 |
| Wei, S | 1 |
| Wang, Q | 1 |
| Liang, Y | 1 |
| Lu, L | 1 |
| Zhang, Y | 5 |
| Zhai, Z | 1 |
| Duan, J | 1 |
| Wang, X | 2 |
| Zhong, J | 2 |
| Wu, L | 2 |
| Li, A | 1 |
| Cao, M | 1 |
| Wu, Y | 2 |
| Shi, H | 1 |
| Guo, Z | 1 |
| Gnocchi, D | 1 |
| Kurzyk, A | 1 |
| Mintrone, A | 1 |
| Lentini, G | 1 |
| Sabbà, C | 1 |
| Mazzocca, A | 1 |
| Lin, J | 1 |
| Lin, Z | 3 |
| Hua, Y | 1 |
| Chen, Y | 4 |
| Dou, Q | 1 |
| Grant, AK | 1 |
| Callahan, C | 1 |
| Coutinho de Souza, P | 1 |
| Mwin, D | 1 |
| Booth, AL | 1 |
| Nasser, I | 1 |
| Moussa, M | 1 |
| Ahmed, M | 1 |
| Tsai, LL | 1 |
| Huang, H | 3 |
| Xue, J | 3 |
| Xie, T | 3 |
| Xie, ML | 3 |
| Sun, T | 1 |
| Zhu, W | 1 |
| Ru, Q | 1 |
| Zheng, Y | 4 |
| Chen, M | 6 |
| Guo, X | 1 |
| Shen, L | 1 |
| Ding, J | 1 |
| Yu, J | 2 |
| Chen, X | 3 |
| Wu, F | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Nakajima, M | 1 |
| Song, J | 1 |
| Shu, G | 1 |
| Ji, J | 2 |
| Xu, H | 2 |
| Li, L | 1 |
| Wang, Z | 5 |
| Qu, L | 1 |
| Bao, X | 2 |
| Li, Y | 3 |
| Zhang, X | 5 |
| Liang, D | 1 |
| Dai, Y | 2 |
| Zheng, QC | 1 |
| Caputo, TM | 1 |
| Cusano, AM | 1 |
| Principe, S | 1 |
| Cicatiello, P | 1 |
| Celetti, G | 1 |
| Aliberti, A | 1 |
| Micco, A | 1 |
| Ruvo, M | 1 |
| Tagliamonte, M | 1 |
| Ragone, C | 1 |
| Minopoli, M | 1 |
| Carriero, MV | 1 |
| Buonaguro, L | 1 |
| Cusano, A | 1 |
| Jiang, R | 1 |
| Luo, S | 1 |
| Zhang, M | 3 |
| Wang, W | 2 |
| Zhuo, S | 1 |
| Qiu, Q | 1 |
| Yuan, Y | 1 |
| Wu, Q | 1 |
| Long, M | 1 |
| Xie, X | 1 |
| Liu, Q | 1 |
| Zhang, J | 5 |
| Dong, K | 1 |
| Li, C | 1 |
| Fang, G | 1 |
| Zhang, P | 2 |
| Liu, J | 3 |
| Zhu, X | 2 |
| Li, R | 2 |
| Park, D | 1 |
| He, Y | 2 |
| Yuan, JJ | 1 |
| Zhu, HH | 1 |
| Shao, LY | 1 |
| Perkons, NR | 1 |
| Johnson, O | 1 |
| Pilla, G | 1 |
| Profka, E | 1 |
| Mercadante, M | 1 |
| Ackerman, D | 1 |
| Gade, TPF | 1 |
| Komoll, RM | 1 |
| Hu, Q | 1 |
| Olarewaju, O | 1 |
| von Döhlen, L | 1 |
| Yuan, Q | 1 |
| Xie, Y | 2 |
| Tsay, HC | 1 |
| Daon, J | 1 |
| Qin, R | 1 |
| Manns, MP | 1 |
| Sharma, AD | 1 |
| Goga, A | 1 |
| Ott, M | 1 |
| Balakrishnan, A | 1 |
| Ma, Q | 1 |
| Yu, M | 1 |
| Zhao, Y | 4 |
| Li, M | 1 |
| Yao, X | 1 |
| Fei, Y | 1 |
| Cai, K | 1 |
| Luo, Z | 1 |
| Nie, Y | 1 |
| Liu, LX | 1 |
| Chen, T | 1 |
| Broadfield, LA | 1 |
| Duarte, JAG | 1 |
| Schmieder, R | 1 |
| Broekaert, D | 1 |
| Veys, K | 1 |
| Planque, M | 1 |
| Vriens, K | 1 |
| Karasawa, Y | 1 |
| Napolitano, F | 1 |
| Fujita, S | 1 |
| Fujii, M | 1 |
| Eto, M | 1 |
| Holvoet, B | 1 |
| Vangoitsenhoven, R | 1 |
| Fernandez-Garcia, J | 1 |
| Van Elsen, J | 1 |
| Dehairs, J | 1 |
| Zeng, J | 1 |
| Dooley, J | 1 |
| Rubio, RA | 1 |
| van Pelt, J | 1 |
| Grünewald, TGP | 1 |
| Liston, A | 1 |
| Mathieu, C | 1 |
| Deroose, CM | 1 |
| Swinnen, JV | 1 |
| Lambrechts, D | 1 |
| di Bernardo, D | 1 |
| Kuroda, S | 1 |
| De Bock, K | 1 |
| Fendt, SM | 1 |
| Feng, Z | 1 |
| Nadikudi, M | 1 |
| Woolley, KL | 1 |
| Hemasa, AL | 1 |
| Chear, S | 1 |
| Smith, JA | 1 |
| Gueven, N | 1 |
| Niu, Y | 1 |
| Wan, A | 1 |
| Sun, L | 1 |
| Yan, S | 1 |
| Liang, H | 1 |
| Zhan, S | 1 |
| Chen, D | 1 |
| Bu, X | 1 |
| Liu, P | 2 |
| Chen, C | 1 |
| He, W | 1 |
| Lu, X | 2 |
| Wan, G | 2 |
| Cai, C | 1 |
| Liu, H | 2 |
| Zou, H | 1 |
| Liu, D | 1 |
| Kong, X | 1 |
| Tang, S | 1 |
| Fu, C | 1 |
| Tan, L | 1 |
| Liu, T | 1 |
| Mao, J | 1 |
| Ren, X | 1 |
| Su, H | 1 |
| Long, D | 1 |
| Chai, Q | 1 |
| Huang, Z | 1 |
| Wang, J | 2 |
| Ren, J | 1 |
| Meng, X | 1 |
| Emami, J | 1 |
| Maghzi, P | 1 |
| Hasanzadeh, F | 1 |
| Sadeghi, H | 1 |
| Mirian, M | 1 |
| Rostami, M | 1 |
| Wan, X | 1 |
| Liu, Y | 1 |
| Sun, X | 2 |
| Fan, D | 1 |
| Guo, L | 1 |
| Kumar, V | 1 |
| Bhatt, PC | 1 |
| Rahman, M | 1 |
| Kaithwas, G | 1 |
| Choudhry, H | 1 |
| Al-Abbasi, FA | 1 |
| Anwar, F | 1 |
| Verma, A | 1 |
| Lee, YK | 2 |
| Lim, JJ | 1 |
| Jeoun, UW | 1 |
| Min, S | 1 |
| Lee, EB | 1 |
| Kwon, SM | 1 |
| Lee, C | 1 |
| Yoon, G | 2 |
| Liang, YJ | 1 |
| Yu, H | 1 |
| Feng, G | 1 |
| Zhuang, L | 1 |
| Xi, W | 1 |
| Ma, M | 1 |
| Chen, J | 3 |
| Gu, N | 1 |
| Kumar, P | 1 |
| Singh, AK | 1 |
| Raj, V | 1 |
| Rai, A | 1 |
| Keshari, AK | 1 |
| Kumar, D | 1 |
| Maity, B | 1 |
| Prakash, A | 1 |
| Maiti, S | 1 |
| Saha, S | 1 |
| Li, F | 1 |
| Wang, F | 1 |
| Zhu, C | 1 |
| Wei, Q | 1 |
| Zhang, T | 1 |
| Zhou, YL | 1 |
| Young, CKJ | 1 |
| Young, MJ | 1 |
| Wang, A | 1 |
| Gong, Z | 1 |
| Biviano, I | 1 |
| Hu, J | 1 |
| Wei, H | 1 |
| Huang, J | 1 |
| Yang, J | 1 |
| Lin, L | 2 |
| Xue, E | 1 |
| Chen, Z | 1 |
| Jung, Y | 1 |
| Jang, YJ | 1 |
| Kang, MH | 1 |
| Park, YS | 1 |
| Oh, SJ | 1 |
| Lee, DC | 1 |
| Xie, Z | 1 |
| Yoo, HS | 1 |
| Park, KC | 1 |
| Yeom, YI | 1 |
| Dai, Q | 2 |
| Yin, Y | 1 |
| Wei, L | 2 |
| You, Q | 1 |
| Lu, N | 2 |
| Guo, Q | 1 |
| Wang, SF | 1 |
| Chou, YC | 1 |
| Mazumder, N | 1 |
| Kao, FJ | 1 |
| Nagy, LD | 1 |
| Guengerich, FP | 1 |
| Huang, C | 1 |
| Lee, HC | 1 |
| Lai, PS | 1 |
| Ueng, YF | 1 |
| Ma, X | 1 |
| Cheng, Z | 1 |
| Jin, Y | 1 |
| Yang, X | 3 |
| Dai, Z | 1 |
| Tian, J | 1 |
| Liu, AM | 1 |
| Xu, Z | 1 |
| Shek, FH | 1 |
| Wong, KF | 1 |
| Lee, NP | 1 |
| Poon, RT | 1 |
| Luk, JM | 1 |
| Darpolor, MM | 2 |
| Basu, SS | 1 |
| Worth, A | 1 |
| Nelson, DS | 1 |
| Clarke-Katzenberg, RH | 2 |
| Glickson, JD | 1 |
| Kaplan, DE | 1 |
| Blair, IA | 1 |
| El Sayed, SM | 1 |
| Mohamed, WG | 1 |
| Seddik, MA | 1 |
| Ahmed, AS | 1 |
| Mahmoud, AG | 1 |
| Amer, WH | 1 |
| Helmy Nabo, MM | 1 |
| Hamed, AR | 1 |
| Ahmed, NS | 1 |
| Abd-Allah, AA | 1 |
| Dangi, R | 1 |
| Hurkat, P | 1 |
| Jain, A | 2 |
| Shilpi, S | 1 |
| Gulbake, A | 1 |
| Jain, SK | 1 |
| Ouyang, H | 1 |
| Zhou, S | 1 |
| Li, J | 2 |
| Ye, Y | 1 |
| Nasr, M | 1 |
| Nafee, N | 1 |
| Saad, H | 1 |
| Kazem, A | 1 |
| Gao, M | 1 |
| Liu, KX | 1 |
| Zhang, CH | 1 |
| Jiang, N | 1 |
| Chu, QC | 1 |
| Guan, X | 1 |
| Tian, Y | 1 |
| Fang, X | 3 |
| Zhou, D | 1 |
| Wang, Y | 4 |
| Kilcup, N | 1 |
| Tonkopi, E | 1 |
| Abraham, RJ | 1 |
| Boyd, D | 1 |
| Kehoe, S | 1 |
| Hou, ZH | 1 |
| Zhao, WC | 1 |
| Zhang, Q | 1 |
| Zheng, W | 1 |
| Jiang, Z | 1 |
| Xiang, L | 1 |
| Ou, M | 1 |
| Shao, J | 1 |
| Lu, Y | 2 |
| Jia, L | 1 |
| Jiang, J | 1 |
| Chen, H | 2 |
| Yu, C | 1 |
| Tian, S | 1 |
| Sun, C | 1 |
| Pan, X | 1 |
| Wu, C | 1 |
| Gao, DY | 1 |
| Lin, TsT | 1 |
| Sung, YC | 1 |
| Liu, YC | 1 |
| Chiang, WH | 1 |
| Chang, CC | 1 |
| Liu, JY | 1 |
| Yin, Q | 1 |
| Qiao, C | 1 |
| Guo, Y | 2 |
| Ma, S | 1 |
| Chen, F | 1 |
| Song, K | 1 |
| Kwon, H | 1 |
| Han, C | 1 |
| Dash, S | 1 |
| Lim, K | 1 |
| Wu, T | 1 |
| Zhu, D | 1 |
| Tao, W | 1 |
| Zhang, H | 2 |
| Liu, G | 1 |
| Wang, T | 1 |
| Zhang, L | 1 |
| Zeng, X | 1 |
| Mei, L | 1 |
| Lee, MJ | 1 |
| Lee, SJ | 2 |
| Yun, SJ | 1 |
| Jang, JY | 1 |
| Kang, H | 1 |
| Kim, K | 1 |
| Choi, IH | 1 |
| Park, S | 1 |
| You, Y | 1 |
| Ran, H | 2 |
| Wang, D | 2 |
| Xu, J | 1 |
| Li, P | 2 |
| Zhang, C | 1 |
| An, T | 1 |
| Zhang, S | 1 |
| Yan, M | 1 |
| Solorio, L | 1 |
| Wu, H | 2 |
| Hernandez, C | 1 |
| Gangolli, M | 1 |
| Exner, AA | 1 |
| Brandt, AP | 1 |
| Gozzi, GJ | 1 |
| Pires, Ado R | 1 |
| Martinez, GR | 1 |
| Dos Santos Canuto, AV | 1 |
| Echevarria, A | 1 |
| Di Pietro, A | 1 |
| Cadena, SM | 1 |
| Mullick Chowdhury, S | 1 |
| Wang, TY | 1 |
| Bachawal, S | 1 |
| Devulapally, R | 2 |
| Choe, JW | 1 |
| Abou Elkacem, L | 1 |
| Yakub, BK | 1 |
| Wang, DS | 1 |
| Tian, L | 1 |
| Paulmurugan, R | 2 |
| Willmann, JK | 2 |
| Fang, XB | 1 |
| Xu, YQ | 1 |
| Chan, HF | 1 |
| Wang, CM | 1 |
| Zheng, Q | 1 |
| Xiao, F | 1 |
| Chen, MW | 1 |
| Situ, JQ | 1 |
| Wang, XJ | 1 |
| Zhu, XL | 1 |
| Xu, XL | 1 |
| Kang, XQ | 1 |
| Hu, JB | 1 |
| Lu, CY | 1 |
| Ying, XY | 1 |
| Yu, RS | 1 |
| You, J | 1 |
| Du, YZ | 1 |
| Foygel, K | 1 |
| Sekar, TV | 1 |
| Liang, B | 1 |
| Zuo, GQ | 1 |
| Zheng, YY | 1 |
| He, S | 1 |
| Zuo, DY | 1 |
| Kou, G | 1 |
| Li, B | 1 |
| Zhang, D | 1 |
| Hou, S | 1 |
| Qian, W | 1 |
| Dai, J | 1 |
| Zhao, J | 1 |
| Zhong, Y | 1 |
| Pereira da Silva, AP | 1 |
| El-Bacha, T | 1 |
| Kyaw, N | 1 |
| dos Santos, RS | 1 |
| da-Silva, WS | 1 |
| Almeida, FC | 1 |
| Da Poian, AT | 1 |
| Galina, A | 1 |
| Uen, YH | 1 |
| Ko, PH | 1 |
| Yin, PH | 1 |
| Liu, TY | 1 |
| Chi, CW | 1 |
| Lui, WY | 1 |
| Díez, S | 1 |
| Navarro, G | 1 |
| de ILarduya, CT | 1 |
| Loiseau, D | 1 |
| Morvan, D | 1 |
| Chevrollier, A | 1 |
| Demidem, A | 1 |
| Douay, O | 1 |
| Reynier, P | 1 |
| Stepien, G | 1 |
| Evenou, F | 1 |
| Fujii, T | 1 |
| Sakai, Y | 2 |
| Reddy, SK | 1 |
| Austin, SL | 1 |
| Spencer-Manzon, M | 1 |
| Koeberl, DD | 1 |
| Clary, BM | 1 |
| Desai, DM | 1 |
| Smith, AD | 1 |
| Kishnani, PS | 1 |
| Liu, ZM | 1 |
| Li, XX | 1 |
| Yan, LN | 1 |
| Harm, S | 1 |
| Stroble, K | 1 |
| Hartmann, J | 1 |
| Falkenhagen, D | 1 |
| Fiume, L | 1 |
| Manerba, M | 1 |
| Vettraino, M | 1 |
| Di Stefano, G | 1 |
| Song, XR | 1 |
| He, G | 1 |
| Luo, YF | 1 |
| He, ZY | 1 |
| Li, SZ | 1 |
| Li, JM | 1 |
| Yu, S | 1 |
| Luo, X | 1 |
| Hou, SX | 1 |
| Wei, YQ | 1 |
| Jin, C | 1 |
| Qian, N | 1 |
| Zhao, W | 1 |
| Yang, W | 1 |
| Bai, L | 1 |
| Wang, M | 1 |
| Song, W | 1 |
| Dou, K | 1 |
| Ueno, S | 1 |
| Sakoda, M | 1 |
| Kurahara, H | 1 |
| Iino, S | 1 |
| Minami, K | 1 |
| Ando, K | 1 |
| Mataki, Y | 1 |
| Maemura, K | 1 |
| Ishigami, S | 1 |
| Shinchi, H | 1 |
| Natsugoe, S | 1 |
| Kim, JH | 1 |
| Kim, EL | 1 |
| Park, CB | 1 |
| Kim, BW | 1 |
| Wang, HJ | 1 |
| Yoon, CH | 1 |
| Yen, YF | 1 |
| Chua, MS | 1 |
| Xing, L | 1 |
| Shi, W | 1 |
| Mayer, D | 1 |
| Josan, S | 1 |
| Hurd, RE | 1 |
| Pfefferbaum, A | 1 |
| Senadheera, L | 1 |
| So, S | 1 |
| Hofmann, LV | 1 |
| Glazer, GM | 1 |
| Spielman, DM | 1 |
| Ao, M | 1 |
| Qing, L | 1 |
| Ouattara, DA | 1 |
| Prot, JM | 1 |
| Bunescu, A | 1 |
| Dumas, ME | 1 |
| Elena-Herrmann, B | 1 |
| Leclerc, E | 1 |
| Brochot, C | 1 |
| Ye, G | 1 |
| Zhu, B | 1 |
| Yao, Z | 1 |
| Yin, P | 1 |
| Kong, H | 1 |
| Fan, F | 1 |
| Jiao, B | 1 |
| Xu, G | 1 |
| Chan, IS | 1 |
| Guy, CD | 1 |
| Lu, J | 1 |
| Swiderska-Syn, M | 1 |
| Michelotti, GA | 1 |
| Karaca, G | 1 |
| Xie, G | 1 |
| Krüger, L | 1 |
| Syn, WK | 1 |
| Anderson, BR | 1 |
| Pereira, TA | 1 |
| Choi, SS | 1 |
| Baldwin, AS | 1 |
| Diehl, AM | 1 |
| Mizumoto, C | 1 |
| Kawabata, H | 1 |
| Uchiyama, T | 1 |
| Sakamoto, S | 1 |
| Kanda, J | 1 |
| Tomosugi, N | 1 |
| Takaori-Kondo, A | 1 |
| Shiokawa, H | 1 |
| Akata, T | 1 |
| Yoshino, J | 1 |
| Kandabashi, T | 1 |
| Kanna, T | 1 |
| Takahashi, S | 1 |
| Perrin, A | 1 |
| Roudier, E | 1 |
| Duborjal, H | 1 |
| Bachelet, C | 1 |
| Riva-Lavieille, C | 1 |
| Leverve, X | 1 |
| Massarelli, R | 1 |
| Qian, J | 1 |
| Truebenbach, J | 1 |
| Graepler, F | 1 |
| Pereira, P | 1 |
| Huppert, P | 1 |
| Eul, T | 1 |
| Wiemann, G | 1 |
| Claussen, C | 1 |
| He, Q | 2 |
| Zhang, ZR | 2 |
| Xu, CQ | 1 |
| Marín-Hernández, A | 1 |
| Rodríguez-Enríquez, S | 1 |
| Vital-González, PA | 1 |
| Flores-Rodríguez, FL | 1 |
| Macías-Silva, M | 1 |
| Sosa-Garrocho, M | 1 |
| Moreno-Sánchez, R | 1 |
| Kojima, N | 1 |
| Matsuo, T | 1 |
| Zhang, B | 1 |
| Chen, W | 1 |
| Dong, W | 1 |
| Cai, MY | 1 |
| Kiseleva, EP | 1 |
| Puzyreva, VP | 1 |
| Ogurtsov, RP | 1 |
| Takahashi, M | 1 |
| Sakurai, M | 1 |
| Enosawa, S | 1 |
| Omasa, T | 1 |
| Tsuruoka, S | 1 |
| Matsumura, T | 1 |
| Maher, JC | 1 |
| Wangpaichitr, M | 1 |
| Savaraj, N | 1 |
| Kurtoglu, M | 1 |
| Lampidis, TJ | 1 |
| Nagamine, T | 1 |
| Saito, S | 1 |
| Yamada, S | 1 |
| Arai, T | 1 |
| Takehara, K | 1 |
| Fukui, T | 1 |
| Bismut, H | 1 |
| Caron, M | 1 |
| Coudray-Lucas, C | 1 |
| Capeau, J | 1 |
| Nishijima, T | 1 |
| Nishina, M | 1 |
| Fujiwara, K | 1 |
| Dupriez, VJ | 1 |
| Rousseau, GG | 1 |
| Pan-Zhou, XR | 1 |
| Cui, L | 1 |
| Zhou, XJ | 1 |
| Sommadossi, JP | 1 |
| Darley-Usmar, VM | 1 |
| Hugo-Wissemann, D | 1 |
| Anundi, I | 1 |
| Lauchart, W | 1 |
| Viebahn, R | 1 |
| de Groot, H | 1 |
| Mizobuchi, N | 1 |
| Kuwao, F | 1 |
| Takeda, I | 1 |
| Takemura, T | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Takahashi, I | 1 |
| Ichihara, T | 2 |
| Sakamoto, K | 2 |
| Mori, K | 2 |
| Akagi, M | 2 |
| Ikei, S | 1 |
| Katauchi, S | 1 |
| Beppu, T | 1 |
| Nokano, M | 1 |
| Tuni, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lactic acid and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Lactate: The Mediator of Metabolism and Immunosuppression.
Topics: Carcinoma, Hepatocellular; Glycolysis; Humans; Immunosuppression Therapy; Lactic Acid; Liver Neoplas | 2022 |
Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.
Topics: Acetaminophen; Adult; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Enz | 2014 |
1 trial available for lactic acid and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Safety and efficacy of early postoperative hyperbaric oxygen therapy with restriction of transfusions in patients with HCC who have undergone partial hepatectomy.
Topics: Aged; Blood Loss, Surgical; Carcinoma, Hepatocellular; Disease-Free Survival; Erythrocyte Transfusio | 2011 |
113 other studies available for lactic acid and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Biodegradable poly(lactide-co-glycolide) microspheres encapsulating hydrophobic contrast agents for transarterial chemoembolization.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast | 2022 |
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunotherapy; Lactic Acid; Liver Neoplasms; Mice; Monoc | 2023 |
Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance.
Topics: alpha-Tocopherol; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; | 2022 |
Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Trans | 2022 |
Nano co-delivery of Plumbagin and Dihydrotanshinone I reverses immunosuppressive TME of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Furans; Lactic Acid; Li | 2022 |
Differential response of hepatocellular carcinoma glycolytic metabolism and oxidative stress markers after exposure to human amniotic membrane proteins.
Topics: Amnion; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Glucose; Glycolysis; Humans; Lactic | 2022 |
Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Lactic Acid; Liver Neoplasms; M | 2022 |
Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Glycolysis; Humans; Lactic Acid; Liver Neoplasms; Oxidative Phosphorylati | 2022 |
Circ_0031242 regulates the functional properties of hepatocellular carcinoma cells through the miR-944/MAD2L1 axis.
Topics: Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Lactic | 2023 |
PFKFB3-mediated Pro-glycolytic Shift in Hepatocellular Carcinoma Proliferation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Glycolysis; Lactic Acid; Liver Neoplasms; Ph | 2023 |
Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Coumarins; Glycogen Synt | 2023 |
Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Coumarins; Glycogen Synt | 2023 |
Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Coumarins; Glycogen Synt | 2023 |
Osthole increases the radiosensitivity of hepatoma cells by inhibiting GSK-3β/AMPK/mTOR pathway-controlled glycolysis.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Coumarins; Glycogen Synt | 2023 |
Silencing RPL8 inhibits the progression of hepatocellular carcinoma by down-regulating the mTORC1 signalling pathway.
Topics: Carcinoma, Hepatocellular; Humans; Lactic Acid; Liver Neoplasms; Mechanistic Target of Rapamycin Com | 2023 |
Monodisperse CaCO
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Drug Carriers; Gela | 2023 |
Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Histones; Humans; Lactic Acid; Liver Neoplasms | 2023 |
d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Immunosuppressive Agents; Lactic Acid; Liver N | 2023 |
Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Humans; Lactic Acid; Liver Neoplasms; Na | 2023 |
Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glucose; Hi | 2023 |
Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Histones; Humans; Lactic Acid; Liver Neoplasms; Lysine; Nuclear Receptor | 2023 |
Characteristics of lactate metabolism phenotype in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cluster Analysis; Humans; Lactic Acid; Liver Neoplasms; Phenotype; Progno | 2023 |
Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antibodies, Monoclonal, Humanized; Carcinoma, | 2019 |
Metformin Induces Oxidative Stress-Mediated Apoptosis without the Blockade of Glycolysis in H4IIE Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Glucos | 2019 |
[Effect of ultrasound contrast agent targeting gelatin on uptake of mouse ascites hepatocellular carcinoma cell lines with high lymphatic metastasis].
Topics: Animals; Ascites; Carcinoma, Hepatocellular; Cell Line; Contrast Media; Diagnostic Imaging; Gelatin; | 2020 |
Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.
Topics: Animals; Carbon-13 Magnetic Resonance Spectroscopy; Carcinoma, Hepatocellular; CRISPR-Cas Systems; D | 2020 |
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
Topics: Animals; Biological Transport; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease | 2021 |
QSOX1 promotes mitochondrial apoptosis of hepatocellular carcinoma cells during anchorage-independent growth by inhibiting lipid synthesis.
Topics: Anoikis; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; En | 2020 |
HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Coen | 2020 |
Serum lactate level predicts 6-months mortality in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective study.
Topics: Aged; Ascites; Carcinoma, Hepatocellular; Female; gamma-Glutamyltransferase; Hepatitis B; Hepatitis | 2021 |
Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis.
Topics: Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Citric Acid Cycle; Diet, High-F | 2021 |
Bioactivity Profiles of Cytoprotective Short-Chain Quinones.
Topics: 3-Hydroxybutyric Acid; Adenosine Triphosphate; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferat | 2021 |
Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2021 |
PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Dynamic Light Scatteri | 2017 |
Imaging-guided synergetic therapy of orthotopic transplantation tumor by superselectively arterial administration of microwave-induced microcapsules.
Topics: Animals; Capsules; Carcinoma, Hepatocellular; Doxorubicin; Lactates; Lactic Acid; Liver Neoplasms; M | 2017 |
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.
Topics: Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Hep | 2018 |
Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Citric Acid Cycle; Gene Expression; Gene Expressi | 2017 |
Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2017 |
Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lactic Acid; Membrane Proteins; Mitochondrial P | 2017 |
High-Performance Poly(lactic-co-glycolic acid)-Magnetic Microspheres Prepared by Rotating Membrane Emulsification for Transcatheter Arterial Embolization and Magnetic Ablation in VX
Topics: Animals; Carcinoma, Hepatocellular; Glycols; Lactic Acid; Liver Neoplasms; Magnetics; Microspheres; | 2017 |
Poly(lactic-
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Betulinic Acid; Carcinoma, Hepatoce | 2018 |
miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.
Topics: Aged; Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; | 2018 |
Comparison of HepaRG cells following growth in proliferative and differentiated culture conditions reveals distinct bioenergetic profiles.
Topics: Acetaminophen; Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Diff | 2019 |
Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease.
Topics: Acute-On-Chronic Liver Failure; Adult; Aged; Analysis of Variance; Biomarkers; Carcinoma, Hepatocell | 2019 |
Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Docetaxel; Drug Carriers; Fem | 2013 |
Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
Topics: Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Survival; Gene Expression; Gene | 2013 |
Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biological Transport; Carcinoma, Hepatocellular; Carrier P | 2013 |
7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells.
Topics: Acetylcysteine; Antibiotics, Antineoplastic; Antioxidants; ATP Binding Cassette Transporter, Subfami | 2013 |
SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellu | 2014 |
miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Carrier Proteins; Cell P | 2014 |
The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Aspartic Acid; Carbon Isotopes; Carcinoma, Hepatocellular; | 2014 |
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Delivery Systems; Fluorouracil; Hep | 2014 |
[Effect of PLGA nanoparticles conjugated with anti-OX40/anti-AFP mAbs on cytotoxicity of CTL cells against hepatocellular carcinoma].
Topics: alpha-Fetoproteins; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2014 |
Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; C | 2014 |
A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coumarins; Delayed-Action Preparations; Drug Carri | 2015 |
TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Availability; Carcinoma | 2014 |
Composition-property relationships for radiopaque composite materials: pre-loaded drug-eluting beads for transarterial chemoembolization.
Topics: Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cell Survival; Chemoembolization, Therapeuti | 2015 |
Effect of paclitaxel-loaded nanoparticles on the viability of human hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prol | 2015 |
Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocell | 2014 |
The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Aptamers, Nucleotide; Carcinoma, Hepatocellular; | 2015 |
Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Topics: Acids; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; D | 2015 |
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery | 2015 |
Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Energy Metabolism; Flavonoids; Gene Expression Regulation, | 2016 |
Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Topics: Abietanes; Animals; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Delayed-Ac | 2016 |
Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
Topics: AC133 Antigen; Adenosine Triphosphate; Antigens, CD; Blotting, Western; Carcinoma, Hepatocellular; C | 2015 |
Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Docetaxel; Drug Delivery Systems; Hep G2 Cells; Humans; Indoles; | 2016 |
Silver nanoparticles affect glucose metabolism in hepatoma cells through production of reactive oxygen species.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Glucose; Hep G2 C | 2016 |
Nanoparticle-enhanced synergistic HIFU ablation and transarterial chemoembolization for efficient cancer therapy.
Topics: Angiography; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Dru | 2016 |
Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Delayed-Action Prepar | 2016 |
Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; | 2016 |
Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model.
Topics: Administration, Intravenous; Animals; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Cell L | 2016 |
Impairment of oxidative phosphorylation increases the toxicity of SYD-1 on hepatocarcinoma cells (HepG2).
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Hep G2 Cells; Hepatocytes; | 2016 |
Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs.
Topics: Animals; Antagomirs; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Doxorubicin; Drug Deliv | 2016 |
A Redox-Sensitive and RAGE-Targeting Nanocarrier for Hepatocellular Carcinoma Therapy.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Diterpenes | 2016 |
Multifunctional SPIO/DOX-loaded A54 Homing Peptide Functionalized Dextran-g-PLGA Micelles for Tumor Therapy and MR Imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease | 2016 |
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Ge | 2016 |
[Clinical effect of ultrasound-guided injection of biodegradable poly(lactic-co-glycolic acid)-Fe
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cattle; Ferrosoferric Oxide; Glycolates; | 2016 |
Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Binding, Competitive; Carcinoma, Hepatocellular; Cell P | 2008 |
Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Energy Metabolism; Enzyme Inhibitors; Glyceraldeh | 2009 |
Glucocorticoid protects hepatoma cells against metabolic stress-induced cell death.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Caspases; Cell Cyc | 2008 |
In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Animals; Asialoglycoproteins; Carcinoma, Hepatocellular; Fatty Acids, Monounsatu | 2009 |
Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Cell Re | 2009 |
Spontaneous formation of highly functional three-dimensional multilayer from human hepatoma Hep G2 cells cultured on an oxygen-permeable polydimethylsiloxane membrane.
Topics: Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Proliferation; Dimethylpolysiloxanes; Dose- | 2010 |
Liver transplantation for glycogen storage disease type Ia.
Topics: Adult; Blood Glucose; Carcinoma, Hepatocellular; Cholesterol; Follow-Up Studies; Glycogen Storage Di | 2009 |
[Experimental investigation of hepatic arterial embolism treatment with microsphere encapsulation of adenovirus with HSV-TK gene].
Topics: Adenoviridae; Animals; Carcinoma, Hepatocellular; Embolization, Therapeutic; Genes, Transgenic, Suic | 2009 |
Alginate-encapsulated human hepatoma C3A cells for use in a bioartificial liver device - the hybrid-MDS.
Topics: Albumins; Alginates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromatography | 2009 |
Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, | 2010 |
Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug | 2010 |
Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Cell Line, | 2010 |
Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Respiration; Claudin-1; Glycolysis; Humans; Isoenz | 2011 |
In vivo MRSI of hyperpolarized [1-(13)C]pyruvate metabolism in rat hepatocellular carcinoma.
Topics: Alanine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic | 2011 |
Hematoporphyrin encapsulated PLGA microbubble for contrast enhanced ultrasound imaging and sonodynamic therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Equipment Design; Hematoporphy | 2012 |
Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cell Respiration; Citric Acid Cycle; Energy Metabolism; Glycol | 2012 |
Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry.
Topics: Aconitic Acid; Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Energy Metabolism; Ethanol | 2012 |
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Fatty Liver; Glycolysis; Hedgehog Proteins; Hep | 2012 |
Acidic milieu augments the expression of hepcidin, the central regulator of iron homeostasis.
Topics: Acids; Antimicrobial Cationic Peptides; Carbon Dioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2012 |
[Changes in acid-base balance and blood lactate levels during radio frequency ablation conducted for the treatment of hepatocellular carcinomata in patients with liver cirrhosis].
Topics: Acid-Base Equilibrium; Aged; Carcinoma, Hepatocellular; Catheter Ablation; Female; Hepatectomy; Huma | 2002 |
Pyruvate reverses metabolic effects produced by hypoxia in glioma and hepatoma cell cultures.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Glioma; Glucose; Humans; Hypoxia | 2002 |
Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2003 |
Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells.
Topics: Animals; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxyribonuclease I; | 2004 |
[Study on the preparation of TK-gene nanoparticles and its expression].
Topics: alpha-Fetoproteins; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Deliv | 2004 |
Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Female; Glucose; Glucose-6-Phosphate; Glycol | 2006 |
Rapid hepatic cell attachment onto biodegradable polymer surfaces without toxicity using an avidin-biotin binding system.
Topics: Albumins; Avidin; Biocompatible Materials; Biotin; Blotting, Western; Carcinoma, Hepatocellular; Cel | 2006 |
[Cytotoxicity of cytotoxic T lymphocytes induced by the dendritic cells phagocytosing PLA-AFP218-226 micospheres Against hepatocellular carcinoma cell lines].
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; HLA-A2 Antigen; Hu | 2006 |
Effect of lactate on functional activity of macrophages under normal conditions and during tumor growth.
Topics: Animals; Carcinoma, Hepatocellular; Lactic Acid; Liver Neoplasms; Macrophages, Peritoneal; Male; Mic | 2006 |
Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium; Carcinoma, Hepatocellular; Cell Cu | 2006 |
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.
Topics: Adenosine Triphosphate; Antimetabolites; Apoptosis; Carcinoma, Hepatocellular; Cell Hypoxia; Deoxygl | 2007 |
Biotinidase activity in patients with liver disease.
Topics: 3-Hydroxybutyric Acid; Acute Disease; Adult; Aged; Amidohydrolases; Biotin; Biotinidase; Carcinoma, | 1993 |
Glucose contribution to nucleic acid base synthesis in proliferating hepatoma cells: a glycine-biosynthesis-mediated pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cells, Cultured; Cycloserine; Enzyme Inhibitors; | 1995 |
Measurement of lactate levels in serum and bile using proton nuclear magnetic resonance in patients with hepatobiliary diseases: its utility in detection of malignancies.
Topics: Adult; Aged; alpha-Fetoproteins; Bile; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Bi | 1997 |
Glucose response elements in a gene that codes for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Topics: Animals; Carcinoma, Hepatocellular; Dactinomycin; Enhancer Elements, Genetic; Enzyme Inhibitors; Gen | 1997 |
Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.
Topics: Anti-HIV Agents; Carcinoma, Hepatocellular; Citrate (si)-Synthase; DNA, Mitochondrial; Electron Tran | 2000 |
Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Anaerobiosis; Animals; Carci | 1991 |
[Changes in ketone body ratio and levels of pyruvate and lactate in arterial blood of patients with hepatocellular carcinoma after transcatheter arterial embolization].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Ketones; Lactates; Lactic Acid; Liver; | 1990 |
Transcatheter arterial chemoembolization therapy for hepatocellular carcinoma using polylactic acid microspheres containing aclarubicin hydrochloride.
Topics: Aclarubicin; Adult; Aged; alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Dogs; Embolization | 1989 |
[Transcatheter hepatic arterial embolization therapy using degradable polylactic acid microspheres].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Catheterization; Embolization, | 1985 |